Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

BA-BE Studies: SOP for Handling Analytical Equipment Breakdowns – V 2.0

Posted on By

BA-BE Studies: SOP for Handling Analytical Equipment Breakdowns – V 2.0

Standard Operating Procedure for Handling Analytical Equipment Breakdowns in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/183/2025
Supersedes SOP/BA-BE/183/2022
Page No. Page 1 of 10
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To establish a structured process for managing analytical instrument breakdowns during bioanalytical phases of BA/BE studies, ensuring timely resolution, proper documentation, and continued compliance with regulatory and data integrity standards.

2. Scope

This SOP applies to all analytical equipment used in BA/BE bioanalytical operations, including LC-MS/MS systems, HPLC, centrifuges, nitrogen evaporators, balances, and data acquisition systems.

3. Responsibilities

  • Analyst: Detects and reports breakdowns
immediately, logs preliminary observations.
  • Instrument Engineer/Technician: Performs diagnostics, initiates repair or escalates to service provider.
  • QA Officer: Reviews impact assessment, verifies documentation, and approves reprocessing plan if applicable.
  • Bioanalytical Manager: Oversees root cause analysis, coordinates preventive measures, and ensures continuity of operations.
  • 4. Accountability

    The Head of Bioanalytical Department is accountable for ensuring that all equipment malfunctions are resolved efficiently and documented accurately to prevent compromise of study results or regulatory non-compliance.

    5. Procedure

    5.1 Identification and Immediate Action

    1. Upon observing abnormal instrument behavior (e.g., signal loss, peak distortion, temperature drift), the analyst shall:
      • Pause the run (if safe and feasible)
      • Record the time, sample ID affected, and error details in the instrument logbook
      • Inform the department supervisor and QA
    2. If autosampler is in use, ensure samples are stored in validated conditions during the interruption.

    5.2 Instrument Tagging and Documentation

    1. Affix a “BREAKDOWN – DO NOT USE” tag to the instrument with date, time, and analyst initials.
    2. Log the incident in the Annexure-1: Equipment Breakdown Register including:
      • Instrument ID and type
      • Date and time of breakdown
      • Error codes/messages if any
      • Description of event

    5.3 Diagnostic and Repair Process

    1. The designated technician or engineer shall:
      • Review system logs and perform diagnostic routines
      • Document corrective action in Annexure-2: Repair & Maintenance Log
      • Replace or recalibrate affected components
    2. If external service is required, raise a service request and record vendor name, visit date, and repair summary.

    5.4 Post-Repair Verification

    1. Conduct system suitability tests (SST) using approved criteria to verify instrument performance.
    2. If SST fails, continue repair and testing until system is restored.
    3. Once qualified, remove breakdown tag and resume routine use.

    5.5 Impact Assessment

    1. QA shall assess the impact of breakdown on:
      • Ongoing runs
      • Sample integrity (e.g., extended storage beyond stability)
      • Calibration standards and QC performance
    2. Document results in Annexure-3: Impact Assessment Form.
    3. Determine need for sample reinjection or reprocessing; get approvals as necessary.

    5.6 Preventive Measures

    1. Review breakdown trend quarterly to identify repetitive failure points.
    2. Implement preventive maintenance and training schedules to reduce recurrence.

    6. Abbreviations

    • BA/BE: Bioavailability/Bioequivalence
    • LC-MS/MS: Liquid Chromatography–Mass Spectrometry
    • SST: System Suitability Test
    • QA: Quality Assurance

    7. Documents

    1. Equipment Breakdown Register – Annexure-1
    2. Repair & Maintenance Log – Annexure-2
    3. Impact Assessment Form – Annexure-3

    8. References

    • ICH Q9: Quality Risk Management
    • 21 CFR Part 11 – Electronic Records
    • Internal Equipment Maintenance SOP

    9. SOP Version

    Version: 2.0

    10. Approval Section

    Prepared By Checked By Approved By
    Signature
    Date
    Name
    Designation
    Department

    11. Annexures

    Annexure-1: Equipment Breakdown Register

    Instrument ID Date Time Description Reported By
    LCMS-03 15/04/2025 11:20 AM No signal detected from detector Rajesh Kumar

    Annexure-2: Repair & Maintenance Log

    Date Action Taken Component Replaced Performed By Remarks
    15/04/2025 Recalibrated MS source N/A Service Engineer System stable post calibration

    Annexure-3: Impact Assessment Form

    Run ID Affected Samples Storage Time Stability Confirmed Reprocessing Required QA Review
    BAE-083 Sample 12–22 48 hrs Yes No Approved

    Revision History:

    Revision Date Revision No. Details Reason Approved By
    01/01/2022 1.0 Initial SOP Issue New SOP QA Head
    17/04/2025 2.0 Inclusion of impact assessment and preventive action Process improvement QA Head
    See also  BA-BE Studies: SOP for Ensuring Study Staff Role Clarity - V 2.0
    BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

    Post navigation

    Previous Post: API Manufacturing: SOP for Reprocessing and Rework Authorization – V 2.0
    Next Post: Sterile Injectable Manufacturing: SOP for Handling Breakages in the Filling Line – V 2.0

    Standard Operating Procedures V 1.0

    • Aerosols
    • Analytical Method Development
    • Bioequivalence Bioavailability Study
    • Capsule Formulation
    • Clinical Studies
    • Creams
    • Data Integrity
    • Dental Dosage Forms
    • Drug Discovery
    • Environment, Health and Safety
    • Formulation Development
    • Gels
    • Good Distribution Practice
    • Good Warehousing Practices
    • In-Process Control
    • Injectables
    • Liquid Orals
    • Liposome and Emulsion Formulations
    • Lotions
    • Lyophilized Products
    • Maintenance Dept.
    • Medical Devices
    • Metered-Dose Inhaler
    • Microbiology Testing
    • Nanoparticle Formulation
    • Nasal Spray Formulations
    • Nebulizers
    • Ocular (Eye) Dosage Forms
    • Ointments
    • Otic (Ear) Dosage Forms
    • Pharmacovigilance
    • Powder & Granules
    • Purchase Departments
    • Quality Assurance
    • Quality Control
    • Raw Material Stores
    • Regulatory Affairs
    • Tablet Manufacturing
    • Rectal Dosage Forms
    • Transdermal Patches
    • Vaginal Dosage Forms
    • Validations and Qualifications

    Read SOPs in your Language:

     - 
    Bengali
     - 
    bn
    English
     - 
    en
    Gujarati
     - 
    gu
    Hindi
     - 
    hi
    Malayalam
     - 
    ml
    Marathi
     - 
    mr
    Punjabi
     - 
    pa
    Tamil
     - 
    ta
    Telugu
     - 
    te

    NEW! Revised SOPs – V 2.0

    • Aerosols V 2.0
    • Analytical Method Development V 2.0
    • API Manufacturing V 2.0
    • BA-BE Studies V 2.0
    • Biosimilars V 2.0
    • Capsules V 2.0
    • Creams V 2.0
    • Elixers V 2.0
    • Gels V 2.0
    • Injectables V 2.0
    • Ointments V 2.0
    • Raw Material Warehouse V 2.0
    • Tablet Manufacturing V2.0

    New Publication: A must for All.

    Copyright © 2026 SOP Guide for Pharma.

    Powered by PressBook WordPress theme

    Go to mobile version